54981-34-9

Upstream product

• 103-82-2 phenylacetic acid 
• 104-92-7 1-bromo-4-methoxy-benzene 
• 103-80-0 phenylacetyl chloride 

Downstream Products

• 1300581-09-2 6-Bromo-2-methyl-3-phenyl-4H-chromen-4-one 
• 1300581-40-1 6-Bromo-3-phenyl-2-propyl-4H-chromen-4-one 
• 1300581-29-6 tert-butyl (6-bromo-4-oxo-3-phenyl-4H-chromen-2-yl)methylcarbamate 
• 1300581-24-1 6-Bromo-2-ethyl-3-phenyl-4H-chromen-4-one 
• 1300581-26-3 (S)-tert-butyl 1-(6-bromo-4-oxo-3-phenyl-4H-chromen-2-yl)ethylcarbamate 
• 2491-31-8 2-hydroxy-deoxybenzoin 
• 1300582-63-1 2-[(6-amino-9H-purin-9-yl) methyl]-6-bromo-3-phenyl-4H-chromen-4-one 
• 1300582-67-5 6-bromo-2-(morpholinomethyl)-3-phenyl-4H-chromen-4-one 
• 1300582-70-0 2-[(6-amino-9H-purin-9-yl) methyl]-3-phenyl-4H-chromen-4-one 
• 1300582-71-1 2-(morpholinomethyl)-3-phenyl-4H-chromen-4-one 
• 1300582-75-5 2-[(1H-benzo[d]imidazol-1-yl)methyl]-6-bromo-3-phenyl-4H-chromen-4-one 
• 1300582-78-8 6-bromo-2-[(4-methyl-1H-benzo[d]imidazol-1-yl)methyl]-3-phenyl-4H-chromen-4-one 
• 1300582-79-9 2-[(1H-benzo[d]imidazol-1-yl)methyl]-3-phenyl-4H-chromen-4-one 
• 1300582-80-2 2-[(4-methyl-1H-benzo[d]imidazol-1-yl)methyl]-3-phenyl-4H-chromen-4-one 

Relevant academic research and scientific papers

Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors

Monoacylglycerol lipase (MAGL) is the enzyme hydrolyzing the endocannabinoid 2-arachidonoylglycerol (2-AG) to free arachidonic acid and glycerol. Therefore, MAGL is implicated in many physiological processes involving the regulation of the endocannabinoid system and eicosanoid network. MAGL inhibition represents a potential therapeutic target for many diseases, including cancer. Nowadays, most MAGL inhibitors inhibit this enzyme by an irreversible mechanism of action, potentially leading to unwanted side effects from chronic treatment. Herein, we report the discovery of long-chain salicylketoxime derivatives as potent and reversible MAGL inhibitors. The compounds herein described are characterized by a good target selectivity for MAGL and by antiproliferative activities against a series of cancer cell lines. Finally, modeling studies suggest a reasonable hypothetical binding mode for this class of compounds.

NOVEL KINASE MODULATORS

The present invention provides PI3K protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.

Chromone fungicides

Compounds of the formula where one of Z and Y is CO and the other is C-W-R2 and the dotted line indicates a double bond is present where necessary to meet valency requirements, W is O, S(O)n, N(R3), N(R3)(R4), N(R3)O or ON(R3); R1 is hydrogen, or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, phenyl or heterocyclyl group; R2, R3 and R4, which may be the same or different, are as defined above for R1, or are acyl, or R2 and R3 or R2 and R4 or R3 and R4 together with the nitrogen or oxygen to which they are attached form an optionally substituted ring which may contain other hetero atoms; each X, which may be the same as or different from any other X, is halogen, CN, NO2, SF5, B(OH)2, triakylsilyl or a group E, OE or S(O)nE where E is a group as defined hereinbefore for R2 or is optionally substituted amino; or two adjacent groups X together with the atoms to which they are attached form an optionally substituted carbocyclic or heterocyclic ring; n is 0, 1 or 2; and p is 0 to 4 have fungicidal activity. Many of the compounds are novel.